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Abstract
Introduction. Orthopaedic surgeries are major procedures, often associated with perioperative risk. They are espe­
cially challenging for elderly patients afflicted with several comorbidities and cardiovascular risk factors. Currently, 
one of the most frequent types of orthopaedic surgeries is joint alloplasties of hip or knee. The aim of this study 
was to establish the clinical characteristics of hypertensive patients undergoing total hip or knee replacement and to 
describe the frequency of the early complication of the surgery, which is a need for blood transfusion. 
Material and methods. The study enrolled 199 consecutive patients who underwent hip or knee alloplasty. From 
this group patients with previous diagnosis of hypertension were selected for further assessment. All patients were 
screened for presence of cardiovascular risk factors and cardiovascular disease, according to the current guidelines. 
All patients were also followed for the necessity of blood transfusion during the hospitalisation. 
Results. From the screened population 135 patients had previous diagnosis of hypertension and met inclusion cri­
teria (mean age 69.0 ± 9.3 years, 30.4% male). From those patients, 70 (48.1%) underwent knee replacement, and 
65 (51.9%) had hip replacement. As for the prevalence of cardiovascular disease, 16 (11.9%) had coronary artery 
disease, 5 (3.7%) had a history of previous myocardial infarction and 2 (1.5%) had diagnosed heart failure. Cardio­
vascular risk factors were also highly prevalent in the study population, 26 (19.3%) patients had diagnosed dyslip­
idemia, 27 (20.0%) had diabetes and 58 (43.0%) were obese. There were no statistical differences in the prevalence 
of those factors between patients with hip and knee replacement. 33 (24.4%) had blood loss during the operation, 
which led to a need for blood transfusion (19 (29.2%) patients in hip replacement group, and 14 (20%) in knee 
replacement group, p = 0.05). We found no differences in the prevalence of cardiovascular disease and cardiovascular 
risk factors between patients who required and did not require blood transfusion (p > 0.05). 
Conclusions. Hypertensive patients who undergo hip or knee replacement have high prevalence of cardiovascular 
risk factors and other cardiovascular disease, therefore are at high perioperative risk. No differences are seen between 
patients with hip and knee replacement. There is also a high frequency of blood transfusions in this group.
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Backgronud
Total hip and knee arthroplasties are very common 
nowadays, and their number is gradually increasing. 
It is due to the increasing life span and advanced de­
generative and inflammatory arthritis. Those surgeries 
relieve pain and improve patients’ function. They usu­
ally have good clinical outcomes, but sometimes are 
associated with complications i.e. blood loss requiring 
transfusion. [1]. Usually, large amount of blood is lost 
during total hip arthroplasty — it is estimated to be 
around 1510 mL, including hidden loss of 471 mL [2]. 
Hidden blood loss is understood as blood extravasation 
into tissues, residual blood in the joint and loss caused 
by haemolysis. This is the reason why patients often 
need blood transfusion, according to studies 2–70% of 
patients after hip or knee arthroplasty receive a blood 
transfusion [3, 4]. The aim of this study was to estab­
lish the clinical characteristics of hypertensive patients 
undergoing total hip or knee replacement and to de­
scribe the frequency of the early complication of the 
surgery, which is a need for blood transfusion. 
Material and methods
The study was designed to be an observational cohort 
study in order to establish the association between 
clinical characteristics and periprocedural risk in con­
secutive Polish patients undergoing total hip or knee 
replacement surgery in a tertiary University Hospital. 
The study was conducted with respect to the Decla­
ration of Helsinki and an approval form the Ethics 
Committee by the Medical University of Warsaw was 
obtained before the beginning of the study. Written, 
informed consent was obtained from every study 
participant prior to the study enrolment.
The study enrolled 199 consecutive patients who 
underwent hip or knee alloplasty. All patients were 
qualified for the surgery procedure following current 
orthopedic criteria. The study population consisted 
of patients in whom the operation was successfully 
performed, and in whom the medical records al­
lowed valid assessment of blood pressure values and 
current medical treatment.
From this group patients with previous diagnosis of 
hypertension were selected for further assessment pro­
cedure. Diagnosis of arterial hypertension was made 
when office blood pressure was equal or exceeded the 
values of 140 for systolic blood pressure (SBP) and/ 
/or 90 for diastolic blood pressure (DBP). The number 
of required measurements, measure techniques and 
settings were in accordance with the current guidelines 
for arterial hypertension diagnosis and management of 
the ESC and European Society of Hypertension. The 
diagnosis was also made taking prescription hypoten­
sive agents or where there were eligible medical records 
available on previous diagnosis of arterial hypertension. 
All patients were screened for presence of car­
diovascular risk factors and cardiovascular disease, 
according to the current guidelines. Data on demo­
graphics, lifestyle, comorbidity and cardiovascular 
risk factors were obtained. Demographic variables 
analyzed included age and sex. Comorbidities as­
sessed in the study included presence of heart failure, 
diabetes mellitus, stroke or TIA episodes, myocardial 
infarction episodes, peripheral artery disease, dysli­
pidemia, coronary artery disease, important valvular 
defect, asthma, chronic obstructive pulmonary dise­
ase, CABG, PCI, cardiac pacemaker implanted. All 
patients were also screened for other classical and 
non­classical cardiovascular risk factors including dia ­ 
betes mellitus, dyslipidemia, or history of cardiovas­
cular disease. Diagnosis of all factors was made based 
on eligible medical records, taking prescription drugs 
applicable for the respective disease (i.e. hypoglyce­
mic agents for diabetes), or as a de novo diagnosis 
according to the current diagnostic criteria.
All patients were also followed for the necessity of 
blood transfusion during the hospitalisation. Blood 
transfusions were performed according to the current 
guidelines in patients whose clinical status required 
this kind of treatment.
Statistical analysis was performed using the SAS 
software version 21 (SAS Institute, Inc., Cary, NC, 
USA). Continuous data are presented as mean ± 
± standard deviation (SD) and were compared using 
the Mann­Whitney test or Student’s t­test. Categor­
ical variables were compared using either the c2 or 
Fisher’s exact tests. A p value of less than 0.05 was 
considered statistically significant, whereas the con­
fidence intervals (CI) were 95%.
Results
From the screened population 135 (67.8%) patients 
had previous diagnosis of hypertension. The mean 
age of the study population was calculated to be 
69.0 ± 9.3 years, and 30.4% of the study group were 
male. From those patients, 70 (48.1%) underwent 
knee replacement, and 65 (51.9%) had hip replace­
ment. As for the prevalence of cardiovascular disease, 
16 (11.9%) had coronary artery disease, 5 (3.7%) 
had a history of previous myocardial infarction and 
2 (1.5%) had diagnosed heart failure. Cardiovascular 
risk factors were also highly prevalent in the study 
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Table I. Baseline characteristics of the study population
Parameter Value (% or mean ± SD)
Age (years) 69.0 ± 9.3
Male sex 41 (30.4%)
Coronary artery disease 16 (11.9%)
Prior myocardial infarction 5 (3.7%)
Heart failure 2 (1.5%)
Atrial fibrillation 8 (5.9%)
Dyslipidemia 26 (19.3%)
Prior stroke or TIA 3 (2.2%)
Diabetes mellitus 27 (20.0%)
Data are presented as number (%) or mean ± SD. SD — standard deviation, TIA — transient ischaemic attack
Table II. Differences between patients undergoing hip and knee replacement
Parameter Patients with hip replacement (n = 65) Patients with knee replacement (n = 70) p value
Age (years) 67.9 ± 10.8 70.1 ± 7.7 0.45
Male sex 28 (43.1%) 13 (18.6%) 0.03
Coronary artery disease 6 (9.2%) 10 (14.3%) 0.43
Prior myocardial infarction 4 (6.2%) 1 (1.4%) 0.20
Heart failure 2 (3.1%) 0 (0.0%) 0.23
Atrial fibrillation 5 (7.7%) 5 (4.3%) 0.48
Dyslipidemia 11 (16.9%) 15 (21.4%) 0.52
Prior stroke or TIA 1 (1.5%) 2 (2.9%) 1.00
Diabetes mellitus 11 (16.9%) 16 (22.9%) 0.52
Table III. Differences between patients who did and did not need blood transfusion
Parameter Patients with blood transfusion (n = 102) Patients without blood transfusion (n = 33) p value
Age (years) 68.9 ± 9.7 69.5 ± 8.2 0.72
Male sex 30 (29.4%) 11 (33.3%) 0.67
Coronary artery disease 15 (14.7%) 1 (3.0%) 0.12
Prior myocardial infarction 4 (3.9%) 1 (3.0%) 1.00
Heart failure 2 (2.0%) 0 (0.0%) 1.00
Atrial fibrillation 6 (5.9%) 2 (6.1%) 1.00
Dyslipidemia 19 (18.6%) 7 (21.2%) 0.80
Prior stroke or TIA 2 (2.0%) 1 (3.0%) 0.57
Diabetes mellitus 18 (17.6%) 9 (27.2%) 0.32
population, 26 (19.3%) patients had diagnosed dys­
lipidemia, 27 (20.0%) had diabetes and 58 (43.0%) 
were obese. Table I presents detailed characteristics of 
patients included into the study.
There were no statistical differences in the preva­
lence of those factors between patients with hip and 
knee replacement. Detailed characteristics are pre­
sented in the Table II.
When we compared patients with and without 
blood transfusion, we saw that 33 (24.4%) had blood 
loss during the operation, which led to a need for 
blood transfusion (19 (29.2%) patients in hip re­
placement group, and 14 (20%) in knee replacement 
group, p = 0.05). We found no differences in the 
prevalence of cardiovascular disease and cardiovas­
cular risk factors between patients who required and 
did not require blood transfusion (p > 0.05). De­
tailed characteristic is presented in the Table III.
Discussion
The present study showed that hypertensive patients 
undergoing hip or knee alloplasty are at elevated 
risk of early complication of the joint surgery that 
is the need for blood transfusion. Studies show dif­
ferent transfusion rates in knee and hip arthroplas­
ty patients (4,8–63,8% vs 4,3–86,8%). It shows 
thattransfusion rate depends on surgeon’s decision 
and preferences [5]. Another reason requiring blood 
transfusion may be preoperative anaemia, which is 
especially crucial in surgical patients [6]. It has been 
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proven that preoperative anaemia leads, for exam­
ple, to increased perioperative adverse outcomes and 
periprosthetic joint infections [7]. Evaluation of hae­
moglobin level should be provided 3–4 weeks before 
surgery, which allows to correct anaemia and prevent 
serious adverse outcomes. Few of the reasons may 
be nutrient deficiency, chronic renal insufficiency, 
chronic inflammatory disease or even gastrointestinal 
malignancy. Also intraoperative blood loss can be 
limited. Patient’s bleeding tendency needs to be esti­
mated. We ought to look for von Willebrand disease 
or ask whether patient is treated with anti­platelet 
therapy. What is more, adequate positioning of the 
patient and maintenance of patient’s body during 
surgery results in minimizing blood loss. Patients’ 
body temperature kept at normal level results in 
losing 20–25% less blood and improves wound heal­
ing [8], which makes blood transfusion unnecessary. 
Another factor that limits blood loss is tranexamic 
acid. Meta­analysis showed that patients treated with 
tranexamic acid were less likely to require blood 
transfusion then patients from placebo group (11 ran ­ 
domized controlled trials; pooled odds ratio [OR] 
0.16, 95% CI 0.09–0.26) [9]. Additionally, people 
who received tranexamic acid had lower transfusion 
rate in comparison to control group (17% vs. 35%, 
p < 0,001) [10]. Patient with DVT or myocardial 
infarction in history requires extra care while treat­
ing with tranexamic acid. Blood loss depends also 
on postoperative actions. Meta­analysis shows that 
both mild­ and high­flexion of the limb after knee 
surgery reduces total blood loss and reduces trans­
fusion requirements [11]. Post­operative transfusion 
is more often given to older people, woman, people 
with smaller BMI and lower estimated blood vol­
ume. Additionally, those patients present a higher 
prevalence of CAD [12]. Older patients are more 
likely to benefit from blood transfusion due to worst 
toleration of lower haemoglobin and haematocrit 
[13]. For younger patients it would be advisable to 
avoid blood transfusion. They can be protected from 
long­term risks. One of the reasons why allogenic 
blood transfusion should be avoided is a significant­
ly increased surgical­site infection rate after hip or 
knee surgery [14]. Allergic reactions may be another 
argument for abstaining from transfusion. It can 
be caused by blood components — plasma com­
ponents, cytokines. Allergic reactions are common 
source of morbidity [15]. Incorrect blood transfusion 
may lead to circulation overload resulting in pulmo­
nary oedema. It is especially dangerous for people 
with left ventricular dysfunction, renal dysfunction 
or acute myocardial infarction [16]. 
As we showed previously, patients undergoing hip 
and knee replacement are at elevated risk of cardiovas­
cular disease, therefore they should be properly man­
aged and their risk should be carefully stratified [17].
In conclusion, every patient requires preoperative, 
intraoperative and postoperative care to limit blood 
loss and need for blood transfusion. Blood transfu­
sion in patients treated with hip or knee replacement 
is a process that has a risk of multiple associated com­
plications, but on the other hand it can be lifesaving 
procedure. Careful treatment and risk stratification 
scheduled in order to minimise blood loss during the 
procedure can be helpful in reducing consequences 
and improving patients’ prognosis. 
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